Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
暂无分享，去创建一个
J. Berlin | P. Philip | E. Swisher | M. Pishvaian | A. Lowy | E. Chiorean | H. Hochster | K. Guthrie | I. Garrido-Laguna | D. Lew | M. Noel | D. Cardin | J. Suga | F. Jalikis | Andrew M. Lowy | Marcus Smith Noel